Plain-English translation of NCT05842174 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether , a medication that has been used for other conditions for many years, can help improve outcomes when combined with a standard liver cancer treatment called transarterial embolization (TACE). The idea is that cancer cells may survive the TACE procedure by using a survival mechanism called autophagy, and this medication may be able to block that mechanism and help the treatment work better.
While TACE is the standard treatment for people with advanced liver cancer who cannot have surgery, the cancer often comes back and long-term survival is limited. Researchers have discovered that cancer cells may be using a specific survival strategy to resist the effects of TACE, and this medication might be able to block that strategy to make the treatment more effective.
You likely qualify if…
You likely don't qualify if…
You would receive the standard TACE procedure, but with the medication mixed into the treatment being delivered directly into the artery feeding your tumor. After the procedure, you would take the medication by mouth daily for 6 weeks. You would come back for follow-up appointments around 3-4 weeks after treatment for imaging scans, tumor biopsies, and blood tests to see how you are responding. The trial compares patients who receive this medication with those who receive a placebo (inactive pill) to see if the medication helps prevent the cancer from coming back.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States